Menu

The Human Microbiome: Colonization in Health and Disease

Join The Scientist as we navigate the human microbiome by bringing together a panel of experts to discuss how microbiota impact human health.

May 31, 2018
The Scientist Creative Services Team

The Human Microbiome: Colonization in Health and Disease from thescientistllc on Vimeo.

The moment we enter the world, we are inhabited by a plethora of microbes. This microbial colonization changes throughout our life and is impacted by where we grow up, and what we touch, eat, and experience. Events like a fever or a course of antibiotics can cause sudden shifts in our microbiomes, with effects that may last for years or even a lifetime. Join The Scientist as we navigate the human microbiome by bringing together a panel of experts to discuss how microbiota impact human health. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics that are related to their research.

Topics to be covered:

  • Better living through gut microbes
  • Uncovering the world of the vaginal microbiome


Meet the Speakers:

Peter Turnbaugh, PhD
Assistant Professor
Department of Microbiology and Immunology
G.W. Hooper Research Foundation
Chan Zuckerberg Biohub Investigator
University of California San Francisco

Elisabeth Bik, PhD
Scientific Editorial Director
uBiome


January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!